Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board
June 03 2020 - 8:30AM
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on
discovering, developing and commercializing transformative
therapies to treat rare and underserved eye diseases, today
announced the appointment of Dr. Mohamed Genead as chair of the
Ocugen, Inc. Retina Scientific Advisory Board, which is comprised
of prominent experts who provide strategic advice, clinical and
regulatory support, and scientific and industry expertise.
Shankar Musunuri, Ph.D., MBA, Chairman, CEO, and Co-Founder
remarked, “We welcome Dr. Genead as Chair of Ocugen’s Retina
Scientific Advisory Board. His deep experience in
ophthalmology and gene therapy will be instrumental as we advance
our breakthrough modifier gene therapy platform into the clinic
next year.”
“Ocugen has a strong product portfolio to address a variety of
retina diseases that lead to vision loss and blindness. Their
novel gene therapy platform has the opportunity to transform our
drug development process and provide one product to address many
inherited retinal diseases. I am excited about the
opportunity to lead this esteemed scientific advisory board and
support Ocugen’s development strategy,” said Dr. Genead.
Mohamed Genead, M.D.Dr. Genead is an
ophthalmologist/retina specialist/serial entrepreneur, inherited
retinal disease expert, and clinical investigator with over 20
years’ experience in ophthalmology and gene & cell therapy drug
development. Prior to co-founding two ophthalmic companies, Dr.
Genead served as Chief Medical Officer and Executive Vice President
for GenSight Biologics, where he led the clinical development and
medical affairs organization in multiple phase I-III trials,
leveraging disruptive ocular gene therapy and optogenetics
platforms for patients with ocular degenerative diseases. Prior to
GenSight, Dr. Genead was Biogen’s ophthalmology and ocular gene
therapy lead in collaborations with Jean Bennett, M.D., Ph.D. at
the University of Pennsylvania (inventor of Luxturna®, the
scientific foundation for Spark Therapeutics) and Applied Genetic
Technologies Corporation in the execution of multiple retina gene
therapy programs intended for regulatory approvals of ophthalmic
gene therapy products. Dr. Genead spent years in academic medicine
serving as a physician/scientist, co-director of the Center of
Retina Degenerative Diseases and as an Investigator, Department of
Ophthalmology and Visual Sciences, at the University of Illinois in
Chicago. His area of academic interest focused on retinal novel
therapeutics from ocular gene therapy to retina regenerative stem
cell therapies for orphan retina diseases such as Stargardt disease
and Retinitis Pigmentosa. His team were pioneers in using topical
eye drops to treat macular edema associated with retinal
dystrophies. In collaboration with researchers at McGill University
and other research institutions, he discovered a new gene mutation
in patients with Leber congenital amaurosis. He is a member of
numerous professional and honorary societies. He was the primary
and key author for numerous peer-reviewed manuscripts in highly
impact factor scientific journals focusing on ophthalmics clinical
research and novel therapeutics. Dr. Genead completed his
vitreoretinal fellowship at the Department of Ophthalmology and
Visual Sciences at the University of Illinois in Chicago and a
retinal research fellowship at the Medical College of
Wisconsin.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing transformative
therapies to treat rare and underserved eye diseases. Our
breakthrough modifier gene therapy platform has the potential to
treat multiple retinal diseases with one drug – “one to many” and
our novel biologic product candidate aims to offer better therapy
to patients with underserved diseases such as wet age-related
macular degeneration, diabetic macular edema and diabetic
retinopathy. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, which are subject to risks and uncertainties. We may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from our
current expectations. These and other risks and uncertainties are
more fully described in our periodic filings with the Securities
and Exchange Commission (the “SEC”), including the risk factors
described in the section entitled “Risk Factors” in the quarterly
and annual reports that we file with the SEC. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events
or otherwise, after the date of this press release.
Corporate Contact:
Ocugen, Inc.
Kelly Beck
kelly.beck@ocugen.com
+1 484-328-4698
Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024